Breaking News: NVO – Market Insights, Analysis & Latest Updates

LLY
NVO

Weight-loss drugs draw Americans back to the doctor

Powerful weight-loss drugs are increasing diagnoses of obesity-related conditions and fueling patient engagement, while also impacting eligibility for various medical services and surgeries.

investing.com • 16/12/2024 - 11:05 AM

CTLT
NVO

Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say

Novo Holdings has fulfilled all closing conditions for its $16.5 billion acquisition of Catalent, enabling its completion soon, amid scrutiny and EU antitrust approval.

investing.com • 14/12/2024 - 16:53 PM

LLY
NVO

How we got to a global obesity epidemic and how GLP-1 is a game-changer

The article discusses the global obesity epidemic, its causes, and the potential of GLP-1 medications as effective treatments, while noting challenges in access and adherence.

investing.com • 13/12/2024 - 14:09 PM

CTLT
NVO

Novo Holdings' $16.5 billion Catalent buy wins EU antitrust approval

Novo Holdings received EU antitrust approval for its $16.5 billion acquisition of Catalent, with no competition issues reported, allowing closure by year-end.

investing.com • 06/12/2024 - 18:04 PM

LLY
NVO

Eli Lilly to invest $3B in Wisconsin plant expansion

Eli Lilly invests $3 billion to expand its Wisconsin facility, boosting production for Zepbound and diabetes drugs, creating 750 jobs, and addressing medication shortages.

investing.com • 05/12/2024 - 20:55 PM

Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars

Eli Lilly announces a $3 billion investment to expand its Wisconsin plant, boosting production for weight-loss and diabetes drugs amid rising demand and previous shortages.

investing.com • 05/12/2024 - 20:43 PM

NVO

Denmark raises 2025 GDP outlook, benefits from Novo Nordisk's growth

Denmark increases growth outlook to 3.0% for 2024, driven by Novo Nordisk's success amid broader European stagnation. Employment growth notably linked to the pharmaceutical sector.

investing.com • 05/12/2024 - 12:20 PM

LLY
NVO

Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trial

Eli Lilly's Zepbound shows superior weight loss efficacy over Wegovy in a recent trial, achieving 20.2% average weight loss vs. 13.7%, strengthening its market position.

investing.com • 04/12/2024 - 13:06 PM

NVAX
NVO

Novavax sells Czech manufacturing facility to Novo Nordisk for $200 mln

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million, streamlining operations and saving approximately $80 million annually.

investing.com • 04/12/2024 - 10:08 AM

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million to boost its vaccine pipeline and reduce costs, amid struggles with COVID-19 vaccine competition.

investing.com • 04/12/2024 - 08:03 AM

Currency